| 2934.99.05 | 00 | 5-Amino-3-phenyl-1,2,4-thiadiazole (3-Phenyl-5-amino-1,2,4-thiadiazole); 2-Hydroxybenzoxazole (Benzoxazolone); 4-Phenylmorpholine; 1,9-Thianthrenedicarboxylic acid; and Thioxanthene-9-one (Thioxanthone) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
| 2934.99.09 | 00 | 1,2-Benzisothiazolin-3-one | kg | Free | | 15.4¢/kg + 40.5% |
| 2934.99.11 | 00 | 2-tert-Butyl-4-(2,4-dichloro-5- isopropoxyphenyl)- 2-1,3,4- oxadiazolin-5-one; 3-Isopropyl-1H-2,1,3- benzothiadiazin-4-(3H)-one-2,2- dioxide (Bentazon); and O,O-Diethyl-S-[(6-chloro-2- oxobenzoxazolin-3-yl)methyl]¢/phosphorodithioate (Phosalone) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¢/kg + 40.5% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
| 2934.99.70 | 00 | Morpholinoethyl chloride hydrochloride; 2-Methyl-2,5-dioxo-1-oxa-2-phospholan; and (6R-trans)-7-Amino-3-methyl-8-oxo-5- thia-1-azabicyclo[4.2.0]-oct-2-ene-2- carboxylic acid | kg | Free | | 30.5% |
| 2935.00.13 | 00 | (5-[2-Chloro-4-(trifluoromethyl)phenoxy]-¢/(methylsulfonyl)-2-nitrobenzamide) (Fomesafen); N-(2,6-Dichloro-3-methylphenyl)-5-amino-1,3,4- triazole-2-sulfonamide; 2,4-Dichloro-5-sulfamoylbenzoic acid; N-Ethyl-o-toluenesulfonamide; N-Ethyl-p-toluenesulfonamide; 7-(Hexadecylsulfonylamino)-1H-indole; Methyl 5-{[(4,6-dimethoxy-2-pyrimidinyl)amino]- carbonylaminosulfonyl}-3-chloro-1-methyl-1H- pyrazole-4-carboxylate (Halosulfuron methyl); and Mixtures of ortho- and para-toluene sulfonamides | kg | Free | | 15.4¢/kg + 57.5% |
| 2935.00.75 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 57.5% |
| 2936.24.00 | 00 | D- or DL-Pantothenic acid (Vitamin B3 or Vitamin B5) and its derivatives | kg | Free | | 25% |
| 2940..00 | | Sugars, chemically pure, other than sucrose, lactose, maltose, glucose and fructose; sugar ethers, sugar acetals and sugar esters, and their salts, other than products of heading 2937, 2938 or 2939: | | | | |
| 2942.00.03 | 00 | [2,2'-Thiobis(4-(1,1,3,3-tetramethyl-n-butyl)- phenolato)(2,1)]-O,O',S-(1-butanamine), nickel II | kg | Free | | 15.4¢/kg + 46.5% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 46.5% |
| 3001 | | Glands and other organs for organotherapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included: | | | | |
| 3001.20.00 | 00 | Extracts of glands or other organs or of their secretions | kg | Free | | 10% |
| 3001.90.01 | | Other | kg | Free | | Free |
| 3001.90.01 | 10 | Glands and other organs, dried, whether or not powdered: | | | | |
| 3001.90.01 | 10 | Liver | kg | | | |
| 3001.90.01 | 50 | Other | kg | | | |
| 3001.90.01 | 90 | Other | kg | | | |
| 3002 | | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: | | | | |
| 3002.10.01 | | Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes | | Free | | Free |
| 3002.10.01 | 10 | Human blood plasma | kg | | | |
| 3002.10.01 | 20 | Normal human blood sera, whether or not freeze-dried | kg | | | |
| 3002.10.01 | 30 | Human immune blood sera | kg | | | |
| 3002.10.01 | 40 | Fetal Bovine Serum (FBS) | kg | | | |
| 3002.10.01 | 90 | Other | kg | | | |
Harmonized Tariff Schedule of the United States inquiry: gaming
